| pubmed-article:15461912 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15461912 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:15461912 | lifeskim:mentions | umls-concept:C0878773 | lld:lifeskim |
| pubmed-article:15461912 | lifeskim:mentions | umls-concept:C0021167 | lld:lifeskim |
| pubmed-article:15461912 | lifeskim:mentions | umls-concept:C0529351 | lld:lifeskim |
| pubmed-article:15461912 | lifeskim:mentions | umls-concept:C0245561 | lld:lifeskim |
| pubmed-article:15461912 | lifeskim:mentions | umls-concept:C0772089 | lld:lifeskim |
| pubmed-article:15461912 | lifeskim:mentions | umls-concept:C1099677 | lld:lifeskim |
| pubmed-article:15461912 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:15461912 | pubmed:dateCreated | 2004-10-5 | lld:pubmed |
| pubmed-article:15461912 | pubmed:abstractText | This year, the US Food and Drug Administration will approve four new drugs indicated for the treatment of lower urinary tract dysfunction. Darifenacin, solifenacin, and trospium are antimuscarinic agents aimed at relieving the symptoms of overactive bladder and urge incontinence in men and women. Duloxetine will be the first drug approved for the treatment of female stress urinary incontinence. This article presents current data on the efficacy and tolerability of these new agents and invites the reader to decide whether they offer any potential advantages over existing therapies. | lld:pubmed |
| pubmed-article:15461912 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15461912 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15461912 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15461912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15461912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15461912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15461912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15461912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15461912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15461912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15461912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15461912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15461912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15461912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15461912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15461912 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15461912 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:15461912 | pubmed:issn | 1527-2737 | lld:pubmed |
| pubmed-article:15461912 | pubmed:author | pubmed-author:KershenRichar... | lld:pubmed |
| pubmed-article:15461912 | pubmed:author | pubmed-author:HsiehMikeM | lld:pubmed |
| pubmed-article:15461912 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15461912 | pubmed:volume | 5 | lld:pubmed |
| pubmed-article:15461912 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15461912 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15461912 | pubmed:pagination | 359-67 | lld:pubmed |
| pubmed-article:15461912 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:15461912 | pubmed:meshHeading | pubmed-meshheading:15461912... | lld:pubmed |
| pubmed-article:15461912 | pubmed:meshHeading | pubmed-meshheading:15461912... | lld:pubmed |
| pubmed-article:15461912 | pubmed:meshHeading | pubmed-meshheading:15461912... | lld:pubmed |
| pubmed-article:15461912 | pubmed:meshHeading | pubmed-meshheading:15461912... | lld:pubmed |
| pubmed-article:15461912 | pubmed:meshHeading | pubmed-meshheading:15461912... | lld:pubmed |
| pubmed-article:15461912 | pubmed:meshHeading | pubmed-meshheading:15461912... | lld:pubmed |
| pubmed-article:15461912 | pubmed:meshHeading | pubmed-meshheading:15461912... | lld:pubmed |
| pubmed-article:15461912 | pubmed:meshHeading | pubmed-meshheading:15461912... | lld:pubmed |
| pubmed-article:15461912 | pubmed:meshHeading | pubmed-meshheading:15461912... | lld:pubmed |
| pubmed-article:15461912 | pubmed:meshHeading | pubmed-meshheading:15461912... | lld:pubmed |
| pubmed-article:15461912 | pubmed:meshHeading | pubmed-meshheading:15461912... | lld:pubmed |
| pubmed-article:15461912 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15461912 | pubmed:articleTitle | Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine. | lld:pubmed |
| pubmed-article:15461912 | pubmed:affiliation | Division of Urology, University of Vermont School of Medicine, 1775 Williston Road, South Burlington, VT 05403, USA. richard.kershen@vtmednet.org. | lld:pubmed |
| pubmed-article:15461912 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15461912 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15461912 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15461912 | lld:pubmed |
